Aerie Pharmaceuticals Company Profile (NASDAQ:AERI)

About Aerie Pharmaceuticals (NASDAQ:AERI)

Aerie Pharmaceuticals logoAerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company's product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan). The Company's product candidates are designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. Its Rhopressa is a once-daily eye drop. Rhopressa inhibits Rho kinase (ROCK), and the norepinephrine transporter (NET), which are both biochemical targets for lowering IOP. Its Roclatan is a once-daily, fixed-dose combination of Rhopressa and latanoprost, which is a prescribed drug for the treatment of patients with open-angle glaucoma. The Company is engaged in conducting Phase III clinical trial for Roclatan.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:AERI
  • CUSIP: N/A
  • Web: www.aeriepharma.com
Capitalization:
  • Market Cap: $2.35669 billion
  • Outstanding Shares: 36,340,000
Average Prices:
  • 50 Day Moving Avg: $56.74
  • 200 Day Moving Avg: $51.50
  • 52 Week Range: $32.05 - $66.10
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -23.17
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $5.09 per share
  • Price / Book: 12.79
Profitability:
  • EBITDA: ($104,160,000.00)
  • Return on Equity: -85.40%
  • Return on Assets: -40.26%
Debt:
  • Debt-to-Equity Ratio: 0.67%
  • Current Ratio: 22.44%
  • Quick Ratio: 22.45%
Misc:
  • Average Volume: 649,383 shs.
  • Beta: 1.07
  • Short Ratio: 9.87
 

Frequently Asked Questions for Aerie Pharmaceuticals (NASDAQ:AERI)

What is Aerie Pharmaceuticals' stock symbol?

Aerie Pharmaceuticals trades on the NASDAQ under the ticker symbol "AERI."

How were Aerie Pharmaceuticals' earnings last quarter?

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) announced its quarterly earnings results on Tuesday, August, 1st. The company reported ($0.82) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.84) by $0.02. View Aerie Pharmaceuticals' Earnings History.

Where is Aerie Pharmaceuticals' stock going? Where will Aerie Pharmaceuticals' stock price be in 2017?

12 equities research analysts have issued twelve-month price targets for Aerie Pharmaceuticals' shares. Their predictions range from $48.00 to $100.00. On average, they anticipate Aerie Pharmaceuticals' stock price to reach $69.17 in the next year. View Analyst Ratings for Aerie Pharmaceuticals.

What are analysts saying about Aerie Pharmaceuticals stock?

Here are some recent quotes from research analysts about Aerie Pharmaceuticals stock:

  • 1. Mizuho analysts commented, "We expect an approval on or prior to the PDUFA date." (10/16/2017)
  • 2. According to Zacks Investment Research, "Aerie’s efforts on developing two late-stage candidates – Rhopressa and Roclatan – are encouraging. However, with no approved product in its portfolio, Aerie depends heavily on a potential approval of Rhopressa. The company resubmitted new drug application (NDA) for lead candidate Rhopressa in Feb 2017. The FDA determined that the application is sufficiently complete to permit a substantive review and set the PDUFA goal date for the completion of review as Feb 28, 2018. A further delay will impact the growth prospects. A meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee of the FDA has been scheduled for October 13 to review the NDA. A potential approval of Rhopressa in early 2018 and successful commercialization will significantly boost the company’s growth prospects in the global ophthalmic market. Aerie’s shares performed worse than the industry in the last three months." (10/10/2017)
  • 3. HC Wainwright analysts commented, "Blueprint reported a Q1 net loss of $28MM and ended the quarter with $452MM." (5/3/2017)
  • 4. Aegis analysts commented, "We still consider the upcoming Mercury 2 three-month efficacy readout for Roclatan expected before the end of Q2, 2017 as being a potentially share moving event. Higher patients dropout rate seen in Rhopressa arm relative to Timolol arm is not concerning to us. 30% of the patients in the Rhopressa arm of the trial discontinued treatment by month 6 compared to 12% of the patient population in the Timolol arm. The most common reason for discontinuation seen in the Rhopressa arm was related to adverse events, at about 19.4%. 2.2% (8) of the subjects in the Timolol arm dropped out due to adverse events. As a point of reference, given that 47% of patients (118 out of 251 patients) on Rhopressa QD completed the treatment by month 12 in Rocket 2, we estimate a maximum drop-off rate of Rhopressa at 53%. Further, according to results published in Persistency: A New Take on Patient Care" by Schwartz in Review of Ophthalmology 11.4 (2004): 108, the discontinuation rates of 66%/50%/46% for Latanoprost/Travoprost/Bimatoprost were seen at month 3 and 6, with rates increasing to 67%/81%/81%, respectively, at month 12." (4/13/2017)
  • 5. Needham & Company LLC analysts commented, " AERI reported 4Q16 financials and updated ongoing Rhopressa and Roclatan development activities. The Rhopressa NDA was refiled in late Feb following an issue at the third party manufacturer. AERI expects a potential PDUFA in 1Q18 after a standard FDA review and is in the process of building a commercial org in anticipation of a 1H18 product launch. Key data from both Rhopressa and Roclatan are expected in 2Q17: top-line safety data from the ph 3 ROCKET-4 trial and top-line efficacy data from the ph 3 MERCURY-2 trial. AERI expects to file an NDA for Roclatan in late 2017/early 2018. We maintain our Buy rating and slightly adjust our $PT to $58 (from $52) to reflect a model and valuation update." (3/8/2017)

Who are some of Aerie Pharmaceuticals' key competitors?

Who are Aerie Pharmaceuticals' key executives?

Aerie Pharmaceuticals' management team includes the folowing people:

  • Vicente Anido Jr., Ph.D., Chairman of the Board, Chief Executive Officer
  • Thomas A. Mitro, President, Chief Operating Officer
  • Casey C. Kopczynski Ph.D., Co-Founder, Chief Scientific Officer
  • Richard J. Rubino CPA, Chief Financial Officer, Secretary
  • Deanne F. Melloy, Vice President - Marketing
  • Tori Arens, Vice President - Drug Product Manufacturing
  • Eric Carlson, Vice President - Research & Development
  • Gerald D. Cagle Ph.D., Independent Director
  • Richard J. Croarkin, Independent Director
  • Michael M. Du Toit, Independent Director

How do I buy Aerie Pharmaceuticals stock?

Shares of Aerie Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aerie Pharmaceuticals' stock price today?

One share of Aerie Pharmaceuticals stock can currently be purchased for approximately $65.10.


MarketBeat Community Rating for Aerie Pharmaceuticals (NASDAQ AERI)
Community Ranking:  4.0 out of 5 (star star star star)
Outperform Votes:  415 (Vote Outperform)
Underperform Votes:  110 (Vote Underperform)
Total Votes:  525
MarketBeat's community ratings are surveys of what our community members think about Aerie Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Aerie Pharmaceuticals (NASDAQ:AERI) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 11 Buy Ratings
Consensus Rating:Buy (Score: 2.92)
Consensus Price Target: $69.17 (6.25% upside)
Consensus Price Target History for Aerie Pharmaceuticals (NASDAQ:AERI)
Price Target History for Aerie Pharmaceuticals (NASDAQ:AERI)
Analysts' Ratings History for Aerie Pharmaceuticals (NASDAQ:AERI)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/16/2017Canaccord GenuityReiterated RatingBuy -> Positive$65.00 -> $73.00N/AView Rating Details
10/16/2017Needham & Company LLCReiterated RatingBuy -> Buy$65.00 -> $76.00N/AView Rating Details
10/16/2017MizuhoReiterated RatingBuy$70.00N/AView Rating Details
10/11/2017JMP SecuritiesSet Price TargetBuy$68.00N/AView Rating Details
10/11/2017Cantor FitzgeraldReiterated RatingPositive -> Buy$62.00N/AView Rating Details
10/5/2017Cowen and CompanyReiterated RatingBuyN/AView Rating Details
8/2/2017HC WainwrightSet Price TargetBuy$69.00HighView Rating Details
7/28/2017Stifel NicolausReiterated RatingBuy$70.00MediumView Rating Details
5/25/2017AegisBoost Price TargetBuy$63.00 -> $70.00HighView Rating Details
3/9/2017Raymond James Financial, Inc.DowngradeStrong-Buy -> Market Perform$48.00LowView Rating Details
3/8/2017Royal Bank Of CanadaBoost Price TargetOutperform$54.00 -> $55.00MediumView Rating Details
2/17/2017Roth CapitalInitiated CoverageBuy$69.00N/AView Rating Details
10/6/2016Brean CapitalReiterated RatingBuy$48.00 -> $63.00N/AView Rating Details
(Data available from 10/21/2015 forward)

Earnings

Earnings History for Aerie Pharmaceuticals (NASDAQ:AERI)
Earnings by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)
Earnings History by Quarter for Aerie Pharmaceuticals (NASDAQ AERI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/1/2017Q2 2017($0.84)($0.82)ViewListenView Earnings Details
5/2/2017Q1 2017($0.74)($0.76)ViewListenView Earnings Details
3/7/2017Q4 2016($0.67)($0.87)ViewListenView Earnings Details
11/2/2016Q316($0.70)($0.67)ViewN/AView Earnings Details
8/3/2016Q216($0.74)($0.72)ViewN/AView Earnings Details
5/2/2016Q116($0.64)($0.72)ViewN/AView Earnings Details
3/1/2016Q415($0.72)($0.64)ViewN/AView Earnings Details
11/3/2015Q315($0.66)($0.69)ViewN/AView Earnings Details
8/5/2015Q215($0.70)($0.73)ViewN/AView Earnings Details
5/7/2015Q1 2015($0.62)($0.70)ViewListenView Earnings Details
3/2/2015Q414($0.51)($0.69)ViewN/AView Earnings Details
11/11/2014Q3 2014($0.40)($0.54)ViewN/AView Earnings Details
8/6/2014Q2 2014($0.37)($0.49)ViewN/AView Earnings Details
5/12/2014Q1 2014($0.35)($0.28)ViewN/AView Earnings Details
3/18/2014Q413($0.25)($0.62)ViewN/AView Earnings Details
12/4/2013Q313($0.25)($10.81)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Aerie Pharmaceuticals (NASDAQ:AERI)
Current Year EPS Consensus Estimate: $-3.09 EPS
Next Year EPS Consensus Estimate: $-2.81 EPS

Dividends

Dividend History for Aerie Pharmaceuticals (NASDAQ:AERI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Aerie Pharmaceuticals (NASDAQ:AERI)
Insider Ownership Percentage: 9.36%
Institutional Ownership Percentage: 94.64%
Insider Trades by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)
Institutional Ownership by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)
Insider Trades by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/26/2017Foresite Capital Fund Ii, L.P.Major ShareholderSell20,000$55.95$1,119,000.00View SEC Filing  
4/19/2017Gerald D CagleDirectorBuy2,000$41.70$83,400.00View SEC Filing  
2/15/2017Geoffrey M DuykDirectorSell41,591$46.63$1,939,388.33View SEC Filing  
10/6/2016Foresite Capital Fund Ii, L.P.Major ShareholderSell50,000$40.34$2,017,000.00View SEC Filing  
7/22/2016Foresite Capital Fund Ii, L.P.Major ShareholderBuy250,000$17.50$4,375,000.00View SEC Filing  
4/15/2015Anand MehraDirectorSell425,000$33.64$14,297,000.00View SEC Filing  
1/8/2015Lifesciences Ii L.P. ClarusMajor ShareholderSell175,000$31.11$5,444,250.00View SEC Filing  
1/5/2015Lifesciences Ii L.P. ClarusMajor ShareholderSell23,620$30.86$728,913.20View SEC Filing  
12/29/2014Lifesciences Ii L.P. ClarusMajor ShareholderSell80,724$30.05$2,425,756.20View SEC Filing  
12/23/2014Lifesciences Ii L.P. ClarusMajor ShareholderSell49,704$30.36$1,509,013.44View SEC Filing  
12/22/2014Lifesciences Ii L.P. ClarusMajor ShareholderSell49,441$30.36$1,501,028.76View SEC Filing  
11/25/2014Anand MehraDirectorSell800,000$26.00$20,800,000.00View SEC Filing  
11/25/2014Group Holdings (Sbs) Advis TpgInsiderSell1,300,000$25.97$33,761,000.00View SEC Filing  
7/10/2014Group Holdings (Sbs) Advis TpgMajor ShareholderSell1,000,000$25.17$25,170,000.00View SEC Filing  
7/9/2014Group Holdings (Sbs) Advis TpgMajor ShareholderSell500,000$25.05$12,525,000.00View SEC Filing  
5/22/2014Anand MehraDirectorSell323,932$16.00$5,182,912.00View SEC Filing  
5/22/2014Iv L.P. AcpMajor ShareholderSell300,000$16.00$4,800,000.00View SEC Filing  
5/16/2014Gerald CagleDirectorBuy1,854$15.07$27,939.78View SEC Filing  
10/30/2013Brian LevyInsiderBuy6,000$10.00$60,000.00View SEC Filing  
10/30/2013Iv L.P. AcpMajor ShareholderBuy110,000$10.00$1,100,000.00View SEC Filing  
10/30/2013Richard J RubinoCFOBuy10,000$10.00$100,000.00View SEC Filing  
10/30/2013Thomas A MitroCOOBuy5,000$10.00$50,000.00View SEC Filing  
10/30/2013Vicente Anido JrCEOBuy28,000$10.00$280,000.00View SEC Filing  
10/25/2013Anand MehraDirectorBuy285,000$10.00$2,850,000.00View SEC Filing  
10/25/2013Lifesciences Ii L.P. ClarusMajor ShareholderBuy321,000$10.00$3,210,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Aerie Pharmaceuticals (NASDAQ:AERI)
Latest Headlines for Aerie Pharmaceuticals (NASDAQ:AERI)
Source:
DateHeadline
bizjournals.com logoStock Performance Review on Drug Makers Industry -- Pfizer, Sanofi, Heron Therapeutics, and Aerie Pharma
www.bizjournals.com - October 20 at 3:45 PM
americanbankingnews.com logoAerie Pharmaceuticals' (AERI) "Positive" Rating Reiterated at Canaccord Genuity
www.americanbankingnews.com - October 16 at 9:54 AM
americanbankingnews.com logoAerie Pharmaceuticals, Inc. (AERI) Earns Buy Rating from Mizuho
www.americanbankingnews.com - October 16 at 6:30 AM
streetinsider.com logoAerie Pharma (AERI) Reports Trading Halt Ahead of Advisory Committee for Rhopressa
www.streetinsider.com - October 14 at 8:29 PM
thestreet.com logoAerie Pharmaceuticals Announces FDA Advisory Committee Vote In Favor Of Rhopressa™ (netarsudil Ophthalmic Solution) 0.02%
www.thestreet.com - October 14 at 8:29 PM
reuters.com logoBRIEF-Aerie Pharmaceuticals says ‍FDA committee to review NDA for Rhopressa
www.reuters.com - October 13 at 8:31 PM
marketwatch.com logoAerie Pharmaceuticals stock halted for FDA committee review of glaucoma treatment - MarketWatch
www.marketwatch.com - October 13 at 3:29 PM
finance.yahoo.com logoAerie Pharmaceuticals Stock Trading Halted Today
finance.yahoo.com - October 13 at 3:29 PM
finance.yahoo.com logoAerie Pharmaceuticals stock halted for FDA committee review of glaucoma treatment
finance.yahoo.com - October 13 at 3:29 PM
finance.yahoo.com logoU.S. FDA panel backs Aerie's glaucoma drug Rhopressa
finance.yahoo.com - October 13 at 3:29 PM
rttnews.com logoAerie Pharmaceuticals Inc. (AERI) Leaped To A New High After FDA Review
www.rttnews.com - October 13 at 2:20 AM
nasdaq.com logoAerie Pharmaceuticals (AERI) Surges: Stock Moves 16.2% Higher - Nasdaq
www.nasdaq.com - October 12 at 4:18 PM
seekingalpha.com logoBiotech Analysis Central: Daily Pharma News - Oct. 12, 2017 - Seeking Alpha
seekingalpha.com - October 12 at 4:18 PM
benzinga.com logoMid-Afternoon Market Update: Hudson Technologies Drops Amid Concerning Guidance; Aerie Pharmaceutical Shares ... - Benzinga
www.benzinga.com - October 12 at 2:41 AM
americanbankingnews.com logoAerie Pharmaceuticals, Inc. (AERI) PT Set at $65.00 by Canaccord Genuity
www.americanbankingnews.com - October 11 at 7:44 PM
msn.com logoAerie Pharma's FDA Briefing Docs: Good News With No Surprises; Shares Scale A Record
www.msn.com - October 11 at 4:38 PM
reuters.com logoAerie's glaucoma drug effectively lowers eye pressure: FDA review
www.reuters.com - October 11 at 4:38 PM
nasdaq.com logoAerie Pharmaceuticals Inc. (AERI) Has Jumped To A New High On FDA News
www.nasdaq.com - October 11 at 4:38 PM
americanbankingnews.com logoAerie Pharmaceuticals, Inc. (AERI) Given a $68.00 Price Target at JMP Securities
www.americanbankingnews.com - October 11 at 4:38 PM
finance.yahoo.com logoStocks Showing Rising Market Leadership: Aerie Pharmaceuticals Earns 82 RS Rating
finance.yahoo.com - October 11 at 4:38 PM
finance.yahoo.com logoFeatured Company News - Aerie Expands Research Team; Set to Focus on Drug Delivery Asset Acquired from Envisia
finance.yahoo.com - October 11 at 4:38 PM
finance.yahoo.com logoFDA review says Aerie glaucoma drug effectively lowers eye pressure; shares jump
finance.yahoo.com - October 11 at 4:38 PM
finance.yahoo.com logoA Drug Sent This Biotech To A Fresh High — But There's A Caveat
finance.yahoo.com - October 11 at 4:38 PM
americanbankingnews.com logoAerie Pharmaceuticals' (AERI) Buy Rating Reaffirmed at Cantor Fitzgerald
www.americanbankingnews.com - October 11 at 11:38 AM
businesswire.com logoAerie Pharmaceuticals Announces Appointment of New Members of its Research and Development Team - Business Wire (press release)
www.businesswire.com - October 9 at 9:45 PM
americanbankingnews.com logoAerie Pharmaceuticals Inc (AERI) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - October 8 at 5:06 PM
americanbankingnews.com logoAerie Pharmaceuticals, Inc. (AERI) Earns Buy Rating from Cowen and Company
www.americanbankingnews.com - October 5 at 4:56 PM
reuters.com logoBRIEF-Aerie Pharmaceuticals announces drug delivery asset acquisition
www.reuters.com - October 5 at 3:24 PM
zacks.com logoJacobs (JEC) Poised to Grow on Divestitures, Contract Wins
www.zacks.com - October 3 at 3:16 PM
businesswire.com logoAerie Pharmaceuticals Announces Appointment of Ann Keevans as Director of Human Resources - Europe - Business Wire (press release)
www.businesswire.com - October 2 at 6:35 AM
reuters.com logoBRIEF-Aerie Pharmaceuticals announces appointment of new members of its commercialization team
www.reuters.com - September 29 at 3:11 PM
marketwatch.com logoAerie Pharmaceuticals Announces Appointment of New Members of its Commercialization Team
www.marketwatch.com - September 29 at 3:11 PM
businesswire.com logoAerie Pharmaceuticals Announces Appointment of New Members of its Commercialization Team - Business Wire (press release)
www.businesswire.com - September 29 at 9:32 AM
americanbankingnews.com logoAerie Pharmaceuticals, Inc. (AERI) Earns Buy Rating from Canaccord Genuity
www.americanbankingnews.com - September 22 at 8:26 PM
nasdaq.com logoFirst Week of AERI May 2018 Options Trading
www.nasdaq.com - September 22 at 2:56 PM
finance.yahoo.com logoCorporate News Blog - Aerie Pharma Appoints Tori Arens as VP of Drug Product Manufacturing and Eric Carlson as VP of R&D
finance.yahoo.com - September 22 at 2:56 PM
businesswire.com logoAerie Pharmaceuticals Announces FDA Advisory Committee Meeting for Rhopressa™ (netarsudil ophthalmic solution ... - Business Wire (press release)
www.businesswire.com - September 20 at 8:33 PM
americanbankingnews.com logoAerie Pharmaceuticals, Inc. (AERI) Stock Rating Reaffirmed by Mizuho
www.americanbankingnews.com - September 20 at 8:20 PM
seekingalpha.com logoJacobs Engineering selected by Aerie Pharmaceuticals as its Engineering Contractor - Seeking Alpha
seekingalpha.com - September 20 at 3:28 PM
nasdaq.com logoJacobs (JEC) Awarded EPCM Contract by Aerie Pharmaceuticals - Nasdaq
www.nasdaq.com - September 20 at 3:28 PM
reuters.com logoBRIEF-Jacobs Engineering selected by Aerie Pharmaceuticals as its engineering contractor for Aerie’S first pharmaceutical manufacturing facility
www.reuters.com - September 19 at 8:36 PM
reuters.com logoBRIEF-Aerie Pharmaceuticals names Tori Arens VP of drug product manufacturing - Reuters
www.reuters.com - September 19 at 3:35 PM
businesswire.com logoJacobs Engineering Selected by Aerie Pharmaceuticals as its Engineering Contractor for Aerie's First Pharmaceutical ... - Business Wire (press release)
www.businesswire.com - September 19 at 3:35 PM
businesswire.com logoAerie Pharmaceuticals Announces Appointment of Tori Arens as Vice President of Drug Product Manufacturing and ... - Business Wire (press release)
www.businesswire.com - September 19 at 3:35 PM
finance.yahoo.com logoAerie Pharmaceuticals Announces Appointment of Tori Arens as Vice President of Drug Product Manufacturing and Eric Carlson, Ph.D. as Vice President of Research and Development
finance.yahoo.com - September 19 at 3:35 PM
americanbankingnews.com logo-$0.62 EPS Expected for Aerie Pharmaceuticals, Inc. (AERI) This Quarter
www.americanbankingnews.com - September 18 at 2:24 AM
americanbankingnews.com logoAerie Pharmaceuticals, Inc. (AERI) Rating Reiterated by Needham & Company LLC
www.americanbankingnews.com - September 17 at 8:58 AM
americanbankingnews.com logoAerie Pharmaceuticals, Inc. (AERI) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - September 13 at 6:43 PM
nasdaq.com logoAre Options Traders Betting on a Big Move in Aerie (AERI) Stock? - Nasdaq
www.nasdaq.com - September 13 at 4:20 PM
finance.yahoo.com logoAre Options Traders Betting on a Big Move in Aerie (AERI) Stock?
finance.yahoo.com - September 13 at 4:20 PM

Social

Chart

Aerie Pharmaceuticals (AERI) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.